For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221223:nRSW6911Ka&default-theme=true
RNS Number : 6911K Faron Pharmaceuticals Oy 23 December 2022
Faron Pharmaceuticals Oy
("Faron" or "Company")
Faron's Financial Calendar for 2023
Company announcement, December 23, 2022 at 9.00 am (EET) / 07:00 AM (GMT) /
02:00 AM (EDT)
TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Oy (AIM: FARN, First
North: FARON), a clinical stage biopharmaceutical company focused on tackling
difficult-to-treat cancers and inflammation via precision immunotherapy, today
announces the following dates for the Company's financial reporting in 2023:
March 2 Financial statement release for the full year 2022
and Annual Report 2022 including financial statements for the full year
August 29 Half-year financial report for the period January 1 to
June 30, 2023
The annual general meeting is planned to be held on March 24, 2023. A separate
stock exchange notice will be issued by Faron's board of directors to convene
the meeting.
For more information please contact:
Investor Contact
Faron Pharmaceuticals
Julia Balanova
VP, Investor Relations
julia.balanova@faron.com (mailto:julia.balanova@faron.com)
investor.relations@faron.com (mailto:investor.relations@faron.com)
Phone: +1 (917) 306-6096
Faron Pharmaceuticals
Toni Hänninen
CFO
toni.hanninen@faron.com (mailto:Yrjo.wichmann@faron.com)
Phone: +41 79 387 2643
Media Contact
Faron Pharmaceuticals
Jennifer Smith-Parker
Head of Communications
Jennifer.Smith-Parker@faron.com (mailto:Jennifer.Smith-Parker@faron.com)
Cairn Financial Advisers LLP, Nomad
Sandy Jamieson, Jo Turner
Phone: +44 (0) 207 213 0880
Peel Hunt LLP, Broker
Christopher Golden, James Steel
Phone: +44 (0) 20 7418 8900
Sisu Partners Oy, Certified Adviser on Nasdaq First North
Juha Karttunen
Phone: +358 (0)40 555 4727
Jukka Järvelä
Phone: +358 (0)50 553 8990
Consilium Strategic Communications
David Daley, Lindsey Neville, Namrata Taak
faron@consilium-comms.com (mailto:faron@consilium-comms.com)
Phone: +44 (0)20 3709 5700
About Faron Pharmaceuticals Ltd
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical
company developing novel treatments for medical conditions with significant
unmet needs caused by dysfunction of our immune system. The Company currently
has a pipeline based on the receptors involved in regulation of immune
response in oncology, organ damage and bone marrow regeneration. Bexmarilimab,
a novel anti-Clever-1 humanized antibody, is its investigative precision
immunotherapy with the potential to provide permanent immune stimulation for
difficult-to-treat cancers through targeting myeloid function. Currently in
Phase I/II clinical development as a potential therapy for patients with solid
tumors and hematologic malignancies, bexmarilimab has potential as a
single-agent therapy or in combination with other standard treatments
including immune checkpoint molecules. Traumakine is an investigational
intravenous (IV) interferon beta-1a therapy for the treatment of acute
respiratory distress syndrome (ARDS) and other ischemic or hyperinflammatory
conditions. Traumakine is currently being evaluated by the 59th Medical Wing
of the US Air Force and the US Department of Defense for the prevention of
multiple organ dysfunction syndrome (MODS) after ischemia-reperfusion injury
caused by a major trauma. Faron is based in Turku, Finland. Further
information is available at www.faron.com (http://www.faron.com) .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NORUUVWRUVUUUAA